Dendritic cell-based immunotherapy in thyroid malignancies

Current Drug Targets. Immune, Endocrine and Metabolic Disorders
Matthias SchottJochen Seissler

Abstract

A new approach for anti-tumor immunotherapy is to use dendritic cells (DCs) as adjuvants in order to actively immunize cancer patients with antigens specifically expressed in tumor cells. DCs possess a unique capacity to effectively activate CD4+ T helper cells and CD8+ cytotoxic T cells. During the last years, several clinical trials in various malignancies demonstrated that immunizations with tumor antigen pulsed DCs could break the tolerance of the immune system against antigens expressed by the tumor cells resulting in partial or complete remission in some cases. This review describes the most important findings on the interaction between DCs and T cells as well as natural killer cells and summarizes recent data on DC vaccination of endocrine and non-endocrine malignancies. The results from current pilot studies suggest that DC vaccination may represent a promising strategy for the development of an anti-cancer vaccine to treat chemotherapy and radioresistant endocrine malignancies.

Citations

May 1, 2006·Expert Review of Endocrinology & Metabolism·William T Scouten, Gary L Francis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Trends in Endocrinology and Metabolism : TEM
Matthias Schott, Jochen Seissler
Current Opinion in Immunology
Gerold SchulerR M Steinman
Seminars in Oncology
Jean-Pascal MachielsMarie Marchand
© 2021 Meta ULC. All rights reserved